Ask AI
BsAbs in RR FL

CE / CME

Bispecific Antibodies in Relapsed/Refractory Follicular Lymphoma: Efficacy, Toxicities, and Practical Implementation

Physician Assistants/Physician Associates: 0.75 AAPA Category 1 CME credit

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.75 Nursing contact hour

Released: February 03, 2026

Expiration: August 02, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Jennifer Crombie, MD, and Farrukh T. Awan, MD, MS, MBA​, explore current and emerging bispecific antibodies used to manage follicular lymphoma (FL) and review key efficacy and safety data for agents such as mosunetuzumab, epcoritamab, and odronextamab.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Please note that Decera Clinical Education plans to measure the educational impact of this activity. Some questions are asked twice: once at the beginning of the activity, and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your individual responses will not be shared. Thank you in advance for helping us assess the impact of this education.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with FL do you provide care for in a typical month?​

For those who practice in academic or community settings, please indicate your practice setting

You are preparing to initiate epcoritamab in a patient with relapsed/refractory (R/R) FL after ≥2 prior lines of therapy. What would you recommend when beginning treatment?

Based on the OLYMPIA-5 trial safety lead-in results exploring odronextamab plus lenalidomide, which of the following findings best reflects a key consideration for safely integrating this bispecific combination regimen into future clinical practice?

A 60-year-old patient with R/R FL is receiving mosunetuzumab. During cycle 1 step-up dosing, the patient develops a fever of 38.8°C without hypotension or hypoxia. Symptoms resolved with antipyretics within 24 hours. Based on current guidelines, how would you manage this patient now?